Oral Administration System Based on Meloxicam Nanocrystals: Decreased Dose Due to High Bioavailability Attenuates Risk of Gastrointestinal Side Effects

Meloxicam (MLX) is widely applied as a therapy for rheumatoid arthritis (RA); however, it takes far too long to reach its peak plasma concentration for a quick onset effect, and gastrointestinal toxicity has been observed in RA patients taking it. To solve these problems, we designed MLX solid nanoparticles (MLX-NPs) by the bead mill method and used them to prepare new oral formulations. The particle size of the MLX-NPs was approximately 20-180 nm, and they remained in the nano-size range for 1 month. The tmax of MLX-NPs was shorter than that of traditional MLX dispersions (MLX-TDs), and the intestinal penetration of MLX-NPs was significantly higher in comparison with MLX-TDs (P < 0.05). Caveolae-dependent endocytosis (CavME), clathrin-dependent endocytosis (CME), and micropinocytosis (MP) were found to be related to the high intestinal penetration of MLX-NPs. The area under the plasma MLX concentration-time curve (AUC) for MLX-NPs was 5-fold higher than that for MLX-TDs (P < 0.05), and the AUC in rats administered 0.05 mg/kg MLX-NPs were similar to rats administered the therapeutic dose of 0.2 mg/kg MLX-TDs. In addition, the anti-inflammatory effect of the MLX-NPs was also significantly higher than that of MLX-TDs at the corresponding dose (P < 0.05), and the therapeutic effect of 0.2 mg/kg MLX-TDs and 0.05 mg/kg MLX-NPs in adjuvant-induced arthritis (AA) rats showed no difference. Furthermore, the gastrointestinal lesions in AA rats treated repetitively with 0.05 mg/kg MLX-NPs were fewer than in rats receiving 0.2 mg/kg MLX-TDs (P < 0.05). In conclusion, we demonstrate that MLX solid nanoparticles allow a quick onset of therapeutic effect and that three endocytosis pathways, CavME, CME, and MP, are related to the high absorption of solid nanoparticles. In addition, we found that MLX solid nanoparticles make it possible to reduce the amount of orally administered drugs, and treatment with low doses of MLX-NPs allows RA therapy without intestinal ulcerogenic responses to MLX. These findings are useful for designing therapies for RA patients.

[1]  Seiji Yamamoto,et al.  Solid Nanocrystals of Rebamipide Promote Recovery from Indomethacin-Induced Gastrointestinal Bleeding , 2019, International journal of molecular sciences.

[2]  F. Ogata,et al.  Combination with l-Menthol Enhances Transdermal Penetration of Indomethacin Solid Nanoparticles , 2019, International journal of molecular sciences.

[3]  F. Ogata,et al.  Energy-dependent endocytosis is responsible for drug transcorneal penetration following the instillation of ophthalmic formulations containing indomethacin nanoparticles , 2019, International journal of nanomedicine.

[4]  N. Nagai,et al.  Energy-Dependent Endocytosis Is Involved in the Absorption of Indomethacin Nanoparticles in the Small Intestine , 2019, International journal of molecular sciences.

[5]  H. Byrne,et al.  Cold Atmospheric Plasma Induces ATP-Dependent Endocytosis of Nanoparticles and Synergistic U373MG Cancer Cell Death , 2018, Scientific Reports.

[6]  F. Sarkar,et al.  Synthesis and characterization of folate decorated albumin bio-conjugate nanoparticles loaded with a synthetic curcumin difluorinated analogue. , 2017, Journal of colloid and interface science.

[7]  J. Pelletier,et al.  Analgesic efficacy of an oral transmucosal spray formulation of meloxicam alone or in combination with tramadol in cats with naturally occurring osteoarthritis. , 2016, Veterinary anaesthesia and analgesia.

[8]  B. Sarriá,et al.  Evaluation of the Bioavailability and Metabolism of Nitroderivatives of Hydroxytyrosol Using Caco-2 and HepG2 Human Cell Models. , 2016, Journal of agricultural and food chemistry.

[9]  N. Nagai,et al.  Pharmacokinetics and Antiinflammatory Effect of a Novel Gel System Containing Ketoprofen Solid Nanoparticles. , 2015, Biological & pharmaceutical bulletin.

[10]  E. Nikolsky,et al.  The effect of dynasore, a blocker of dynamin-dependent endocytosis, on spontaneous quantal and non-quantal release of acetylcholine in murine neuromuscular junctions , 2014, Doklady Biological Sciences.

[11]  F. Martínez,et al.  Solubility and preferential solvation of meloxicam in methanol+water mixtures at 298.15K , 2014 .

[12]  N. Nagai,et al.  Effect of solid nanoparticle of indomethacin on therapy for rheumatoid arthritis in adjuvant-induced arthritis rat. , 2014, Biological & pharmaceutical bulletin.

[13]  Jan P Möschwitzer,et al.  Drug nanocrystals in the commercial pharmaceutical development process. , 2013, International journal of pharmaceutics.

[14]  Takashi Tanaka,et al.  Transepithelial transport of theasinensins through Caco-2 cell monolayers and their absorption in Sprague-Dawley rats after oral administration. , 2012, Journal of agricultural and food chemistry.

[15]  K. Shi,et al.  A novel surface modified nitrendipine nanocrystals with enhancement of bioavailability and stability. , 2012, International journal of pharmaceutics.

[16]  Imre Mäger,et al.  The role of endocytosis on the uptake kinetics of luciferin-conjugated cell-penetrating peptides. , 2012, Biochimica et biophysica acta.

[17]  A. Date,et al.  Positively charged polymeric nanoparticles: application in improving therapeutic efficacy of meloxicam after oral administration. , 2011, Die Pharmazie.

[18]  Jianqing Gao,et al.  Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs , 2010, Expert opinion on drug delivery.

[19]  K. Takeuchi,et al.  Role of endothelial nitric oxide synthase in aggravation of indomethacin-induced gastric damage in adjuvant arthritic rats. , 2009, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[20]  J Kristl,et al.  Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam. , 2009, International journal of pharmaceutics.

[21]  F. Hollfelder,et al.  Fluid phase endocytosis contributes to transfection of DNA by PEI-25. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  Abu T M Serajuddin,et al.  Salt formation to improve drug solubility. , 2007, Advanced drug delivery reviews.

[23]  Filippos Kesisoglou,et al.  Nanosizing--oral formulation development and biopharmaceutical evaluation. , 2007, Advanced drug delivery reviews.

[24]  S. Stainmesse,et al.  Freeze-drying of nanoparticles: formulation, process and storage considerations. , 2006, Advanced drug delivery reviews.

[25]  S. Baumgartner,et al.  Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. , 2006, International journal of pharmaceutics.

[26]  Barrett E. Rabinow,et al.  Nanosuspensions in drug delivery , 2004, Nature Reviews Drug Discovery.

[27]  Raviraj M. Kulkarni,et al.  Nanosuspensions: a promising drug delivery strategy , 2004, The Journal of pharmacy and pharmacology.

[28]  Elaine Merisko-Liversidge,et al.  Nanosizing: a formulation approach for poorly-water-soluble compounds. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[29]  M. Fornai,et al.  Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug , 2002 .

[30]  D. Türck,et al.  Meloxicam oral suspension: a treatment alternative to solid meloxicam formulations , 2001, Inflammation Research.

[31]  J Dressman,et al.  Improving drug solubility for oral delivery using solid dispersions. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[32]  N. Davies,et al.  Clinical Pharmacokinetics of Meloxicam , 1999, Clinical pharmacokinetics.

[33]  J. Morrow,et al.  Meloxicam inhibits the growth of colorectal cancer cells. , 1998, Carcinogenesis.

[34]  W. Ray,et al.  Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. , 1995, American journal of epidemiology.

[35]  J. Fries,et al.  Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. , 1991, The American journal of medicine.

[36]  B. Finlay,et al.  Salmonella interactions with polarized human intestinal Caco-2 epithelial cells. , 1990, The Journal of infectious diseases.

[37]  C. Hopkins,et al.  Basolateral secretion of kappa light chain in the polarised epithelial cell line, Caco-2. , 1989, Journal of cell science.

[38]  Hobbs Dc.  Piroxicam pharmacokinetics: recent clinical results relating kinetics and plasma levels to age, sex, and adverse effects. , 1986 .

[39]  A. Zweibaum,et al.  Epithelial properties of human colonic carcinoma cell line Caco-2: electrical parameters. , 1984, The American journal of physiology.

[40]  J. Amit,et al.  NANOSUSPENSION DRUG DELIVERY , 2012 .

[41]  Hari Singh Nalwa,et al.  Encyclopedia of nanoscience and nanotechnology , 2011 .

[42]  O. G. Nilsen.  Clinical Pharmacokinetics of Tenoxicam , 1994, Clinical pharmacokinetics.

[43]  D. Hobbs.  Piroxicam pharmacokinetics: recent clinical results relating kinetics and plasma levels to age, sex, and adverse effects. , 1986, The American journal of medicine.